Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

Author： Razga Filip   Jurcek Tomas   Zackova Daniela   Dvorakova Dana   Toskova Martina   Jeziskova Ivana   Mayer Jiri   Racil Zdenek  

Publisher： Adis International

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.16, Iss.4, 2012-08, pp. : 251-259

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

BCR-ABL1+ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1- Subclone as a Cause of Refractory Disease with Nilotinib Treatment

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-11 ,pp. : 237-241

Karger

Access to resources Recommend Favorite

BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 34-42

Karger

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite